CRISPR Therapeutics AG
CRSP
주식 순위
#3584
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
주가
$49.25
마지막 동기화: 2026-10-16
시가총액
$4.76B
변동 (1일)
-4.42%
변동 (1년)
-28.78%
국가
CH
거래 CRISPR Therapeutics AG (CRSP)
카테고리
Healthcare
CRISPR Therapeutics AG (CRSP)의 영업이익률
October 2026 기준 영업이익률 TTM: -3,971.53%
CRISPR Therapeutics AG의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 -3,971.53%입니다. 2023년 말 기준 영업이익률은 -59.95%였습니다.
CRISPR Therapeutics AG의 영업이익률 기록 (2014 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | -3,971.53% | 197.93% |
| 2024 | -1,333.05% | 2,123.60% |
| 2023 | -59.95% | -99.96% |
| 2022 | -154,394.72% | -377,500.93% |
| 2021 | 40.91% | -100.06% |
| 2020 | -65,273.48% | -404,520.57% |
| 2019 | 16.14% | -100.32% |
| 2018 | -5,087.80% | 3,126.46% |
| 2017 | -157.69% | -88.05% |
| 2016 | -1,319.33% | -87.33% |
| 2015 | -10,416.60% | 0.00% |
| 2014 | 0.00% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.96% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.01% |
NL
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.